EDGAR Filing Documents for 0001176256-13-000162

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001176256-13-000162

Filing Date

2013-03-15

Accepted

2013-03-15 09:48:43

Documents

Period of Report

2012-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	REPORT OF FOREIGN ISSUER FOR THE PERIOD ENDED DECEMBER 31, 2012	nymox6kafs121231.htm	6-K	5469
2	ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2012	exhibit99-1.htm	EX-99.1	673140
3	SOX SECTION 302 AND 906 CEO CERTIFICATIONS	exhibit99-2.htm	EX-99.2	6320
4	SOX SECTION 302 AND 906 CFO CERTIFICATIONS	exhibit99-3.htm	EX-99.3	6249
5		nymox991p1x1x1.jpg	GRAPHIC	10907
6		ex9911.jpg	GRAPHIC	6920
7		ex9912.jpg	GRAPHIC	3313
	Complete submission text file	0001176256-13-000162.txt		721704

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 5143323222

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 13692408
SIC: 2835 In Vitro & In Vivo Diagnostic Substances